These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
604 related articles for article (PubMed ID: 27220704)
1. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography]. Liu Y; Li L; Xu G; Wang W Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704 [TBL] [Abstract][Full Text] [Related]
2. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637 [TBL] [Abstract][Full Text] [Related]
3. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Cheng CK; Chang CK; Peng CH Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374 [TBL] [Abstract][Full Text] [Related]
4. Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy. van Rijssen TJ; Mohabati D; Dijkman G; Theelen T; de Jong EK; van Dijk EHC; Boon CJF PLoS One; 2018; 13(8):e0202549. PubMed ID: 30142176 [TBL] [Abstract][Full Text] [Related]
5. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol. Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630 [TBL] [Abstract][Full Text] [Related]
7. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Nicolò M; Zoli D; Musolino M; Traverso CE Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224 [TBL] [Abstract][Full Text] [Related]
8. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy. Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561 [TBL] [Abstract][Full Text] [Related]
9. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Chan WM; Lai TY; Lai RY; Liu DT; Lam DS Ophthalmology; 2008 Oct; 115(10):1756-65. PubMed ID: 18538401 [TBL] [Abstract][Full Text] [Related]
10. Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy. Liu HY; Yang CH; Yang CM; Ho TC; Lin CP; Hsieh YT Am J Ophthalmol; 2016 Jul; 167():57-64. PubMed ID: 27084002 [TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Tseng CC; Chen SN Br J Ophthalmol; 2015 Aug; 99(8):1070-7. PubMed ID: 25680621 [TBL] [Abstract][Full Text] [Related]
12. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes. Matušková V; Vysloužilová D; Uher M Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091 [TBL] [Abstract][Full Text] [Related]
13. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy. Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884 [TBL] [Abstract][Full Text] [Related]
14. Half-time photodynamic therapy for central serous chorioretinopathy. Tsai MJ; Hsieh YT Optom Vis Sci; 2014 Sep; 91(9):1140-5. PubMed ID: 25083838 [TBL] [Abstract][Full Text] [Related]
15. Angiographic and Tomographic Prognostic Factors of Chronic Central Serous Chorioretinopathy Treated with Half-Dose Photodynamic Therapy. Chung CY; Chan YY; Li KKW Ophthalmologica; 2018; 240(1):37-44. PubMed ID: 29566395 [TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy. van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468 [TBL] [Abstract][Full Text] [Related]
17. [Photodynamic therapy for treatment of chronic or recurrent central serous chorioretinopathy]. Li L; Yuan F; Xu GZ; Wang WJ Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):106-13. PubMed ID: 22490944 [TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy for steroid-associated central serous chorioretinopathy. Lee TG; Kim JE Br J Ophthalmol; 2011 Apr; 95(4):518-23. PubMed ID: 20679080 [TBL] [Abstract][Full Text] [Related]
19. Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes. Karakus SH; Basarir B; Pinarci EY; Kirandi EU; Demirok A Eye (Lond); 2013 May; 27(5):612-20. PubMed ID: 23519277 [TBL] [Abstract][Full Text] [Related]
20. The one-year results of half-dose photodynamic therapy with verteporfin in chronic or recurrent central serous chorioretinopathy. Jirarattanasopa P; Ratanasukon M; Bhurayanontachai P J Med Assoc Thai; 2012 Apr; 95 Suppl 4():S56-60. PubMed ID: 22696853 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]